Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET

Company Participants

Luis Sanay - Head, IR

John C. Jacobs - President and CEO

Jeffrey Dierks - Chief Commercial Officer

Jeffrey M. Dayno - Chief Medical Officer

Sandip Kapadia - CFO

Conference Call Participants

Danielle Brill - Raymond James

Chris Howerton - Jefferies

Charles Duncan - Cantor Fitzgerald

David Amsellem - Piper Sandler

Corinne Jenkins - Goldman Sachs

Francois Brisebois - Oppenheimer

Operator

Good morning. My name is Ashley and I will be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences First Quarter 2022 Financial Update Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference may be recorded. [Operator Instructions]. I will now turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead.

Luis Sanay

Thank you, operator. Good morning, everyone and thank you for joining us today as we review Harmony Biosciences first quarter 2022 financial performance and provide a business update. Before we start, I encourage everyone to go to the Investors section of our website to find the press release and slides that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance. Our presenters on today's call are John Jacobs, President and CEO; Dr. Jeffrey Dayno, Chief Medical Officer; Jeffrey Dierks, Chief Commercial Officer; and Sandip Kapadia, Chief Financial Officer.

Moving on to Slide 2. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors referenced in our SEC filings for additional details. I would now like to turn the call over to our CEO, John Jacobs. John?

John C. Jacobs

Thank you Luis and thank you everyone for joining our conference call today. During the first quarter we continued to execute on our three pillar growth strategy with progress across all three pillars and achieving two key milestones. We are excited about the momentum we see in the business and as you have heard me say previously, we are looking forward to making 2022 our best year yet.